Zepp Health (ZEPP) Q1 2026 Earnings Transcript

Zepp Health reported Q1 2026 revenue of $51.5 million, up 33.8% year over year, with gross margin expanding to 37.7% and gross profit rising 35.3% to $19.4 million. Management said premium product launches and hybrid-training positioning are driving pricing power, while Q2 revenue guidance was set at $63 million to $68 million, implying 6% to 14% growth. Operating loss narrowed to $6.3 million, inventory fell to $62.8 million, and the company has repurchased $17 million of its $20 million buyback authorization.

Analysis

ZEPP is transitioning from a low-end hardware vendor to a premium training ecosystem, and that matters more for valuation than the headline growth rate. The key second-order effect is that higher-priced models are now acting as a mix engine for the entire portfolio: if the brand can keep converting entry users into premium tiers, gross margin can rise even if unit growth slows. That creates an asymmetric setup where each incremental share gain in endurance/hybrid niches is worth more than in the prior cycle because pricing power is finally becoming visible.

The more interesting competitive angle is not Garmin’s absolute share, but the pressure this puts on mid-tier Android/WearOS-adjacent wearables that lack a community anchor. HYROX gives ZEPP a distribution wedge into a behavior-driven segment, which can lower CAC over time and increase retention through software lock-in; that is a better economic model than paying for generic performance marketing. The flip side is that this strategy only works if product launches remain frequent and differentiated — otherwise the company risks becoming a theme stock with rising spend and fading novelty by late 2H26.

The near-term risk is margin compression from memory and FX, but management is already signaling it can offset part of that with ASP increases and supply diversification. The real catalyst window is the next 1-2 quarters: if Q2 lands toward the top of guidance while opex normalizes in 2H, the market can start underwriting a path to sustained operating leverage. If launch timing slips again, however, the stock likely retraces because the current thesis is heavily dependent on front-loaded launch momentum translating into repeatable demand rather than one-quarter spillover.

Key Decisions for Investors

• Long ZEPP for a 3-6 month catalyst trade; the setup favors upside if Q2 revenue prints near the top of guide and 2H opex normalizes. Risk/reward is attractive only if you use a tight stop below the post-earnings support, because the stock is still execution-dependent.
• Pair trade: long ZEPP / short GRMN over the next 1-2 quarters. ZEPP has more operating torque from mix expansion and brand re-rating, while GRMN is less levered to incremental premiumization; this pair isolates category share and pricing power.
• Buy ZEPP call spreads expiring after the next two earnings prints. The thesis is that the market is underpricing margin recovery if ASP gains persist, but the spread structure limits damage if memory cost inflation or launch slippage delays the re-rate.
• If ZEPP rallies sharply on HYROX enthusiasm, trim into strength rather than chase. The collaboration is strategically real, but the stock could already be discounting several quarters of brand-building before monetization becomes visible.